AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7844680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no carnitine supplementation)
Number of subjects: 43
Study 2190462 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN), 120 mg once daily
Number of subjects: 17
Study 2190462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 20 mg twice daily
Number of subjects: 17
Study 2190462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 348614 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐Amidino‐2‐(2,6‐dichlorophenyl) acetamide hydrochloride (BS 100‐‐141)
Number of subjects: 16
Study 348614 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 16
Study 29415600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adhesions
Number of subjects: 97
Study 29415600 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with adhesion score three
Number of subjects: 97
Study 29415600 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesion severity score
Number of subjects: 97
Study 30113644 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal noise exposure measurements (8 h) using dosimeters
Number of subjects: 163
Study 30113644 — intervention group
Group type: EXPERIMENTAL
Intervention: Area noise measurements (10-s measurements) using a sound level meter
Number of subjects: 163
Study 30113644 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of noise exposure in the furnace section
Number of subjects: 163
Study 30113644 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of noise exposure in the rolling mill section
Number of subjects: 163
Study 25289713 — intervention group
Group type: EXPERIMENTAL
Intervention: RSA cycling
Number of subjects: 0
Study 25289713 — intervention group
Group type: COMPARATOR
Intervention: RSA running
Number of subjects: 0
Study 25402337 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based inductive reasoning training program
Number of subjects: 0
Study 25402337 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based competitive program in creative problem solving
Number of subjects: 0
Study 25402337 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 22948944 — intervention group
Group type: EXPERIMENTAL
Intervention: High Saturated Fat (HSF) diet
Number of subjects: 14
Study 22948944 — intervention group
Group type: COMPARATOR
Intervention: Low Saturated Fat diet
Number of subjects: 14
Study 20587541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UV‐A (25%), UV‐B (5%) and visible light (70%)
Number of subjects: 79
Study 20587541 — intervention group
Group type: COMPARATOR
Intervention: Low‐intensity visible light (Control)
Number of subjects: 79
Study 17624203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjusted to 25 mg or 100 mg as needed)
Number of subjects: 155
Study 17624203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 16264052 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Chrispin-Norman scoring system (CNS)
Number of subjects: 50
Study 16264052 — intervention group
Group type: COMPARATOR
Intervention: Original Chrispin-Norman scoring system (CNS)
Number of subjects: 50
Study 16264052 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CNS
Number of subjects: 50
Study 16264052 — intervention group
Group type: COMPARATOR
Intervention: Original CNS
Number of subjects: 50
Study 11228485 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d for 1 year
Number of subjects: 45
Study 11228485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 9604239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at the right ventricular outflow tract (RVOT)
Number of subjects: 14
Study 9604239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pacing at both RV sites (RVOT and RVA)
Number of subjects: 14
Study 9604239 — intervention group
Group type: COMPARATOR
Intervention: Pacing at the RV apex (RVA)
Number of subjects: 14
Study 7846210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.0, 0.06, 0.13, 0.25, 0.5 mg; total cumulative dose: 0.94 mg)
Number of subjects: 9
Study 7846210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3288775 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 per cent dimethyl sulfoxide
Number of subjects: 33
Study 3288775 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 33
Study 31642331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram-based Cox proportional regression model using 9 biomarkers (Beclin 1, Aurora‐A, Cyclin D1, Ki‐67, P27, Bcl‐2, MMP‐9, 14‐3‐3σ, VCA‐IgA)
Number of subjects: 147
Study 31642331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram algorithm for individual metastasis risk
Number of subjects: 147
Study 28448477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin tannate plus ORS
Number of subjects: 203
Study 26437529 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic therapy using menthol
Number of subjects: 317
Study 26437529 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol group (control)
Number of subjects: 317
Study 26437529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (menthol and non-menthol)
Number of subjects: 317
Study 23400584 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the complete ultrasound module
Number of subjects: 16
Study 23400584 — intervention group
Group type: COMPARATOR
Intervention: Control group with access to only the lumbar anatomy module
Number of subjects: 16
Study 21468614 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (500 mg in 20 ml saline)
Number of subjects: 120
Study 21468614 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine (100 mg in 20 ml 0.5%)
Number of subjects: 120
Study 21468614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam (8 mg in 20 ml saline)
Number of subjects: 120
Study 21468614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml saline)
Number of subjects: 120
Study 20027406 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 42
Study 20027406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20027406 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 42
Study 17037821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/day)
Number of subjects: 298
Study 17037821 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 298
Study 14624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 18
Study 14624184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 18
Study 14624184 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 11123496 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion devices prepared by pharmacy (5 days)
Number of subjects: 8
Study 11123496 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted drugs by patients (5 days)
Number of subjects: 8
Study 9499941 — intervention group
Group type: EXPERIMENTAL
Intervention: sphenoidal angle measurement
Number of subjects: 330
Study 9499941 — intervention group
Group type: EXPERIMENTAL
Intervention: sphenoidal angle as an ageing criterion
Number of subjects: 330
Study 7934445 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infant formula supplemented with Bifidobacterium bifidum and S thermophilus
Number of subjects: 55
Study 7934445 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (control)
Number of subjects: 55
Study 3219525 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled J pouch
Number of subjects: 33
Study 3219525 — intervention group
Group type: COMPARATOR
Intervention: Sutured W pouch
Number of subjects: 33
Study 3219525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both J pouch and W pouch
Number of subjects: 33
Study 29154159 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Eclectic Psychotherapy for PTSD (BEP)
Number of subjects: 116
Study 29154159 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing therapy (EMDR)
Number of subjects: 116
Study 28760425 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (60 μg/d as selenious acid added to PN)
Number of subjects: 20
Study 28760425 — intervention group
Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 20
Study 25695930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program to reduce quartz exposure
Number of subjects: 0
Study 23731375 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg per day
Number of subjects: 171
Study 23731375 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg per day
Number of subjects: 171
Study 23731375 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg per day
Number of subjects: 171
Study 23731375 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg per day, 400 mg per day, and 800 mg per day
Number of subjects: 171
Study 23731375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NAC)
Number of subjects: 171
Study 20090566 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating-heart CPB
Number of subjects: 0
Study 20090566 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump techniques
Number of subjects: 0
Study 20090566 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB
Number of subjects: 0
Study 18405821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental water jet (DWJ) with orthodontic jet tip plus manual toothbrush
Number of subjects: 106
Study 18405821 — intervention group
Group type: EXPERIMENTAL
Intervention: Flossing (FL) plus manual toothbrush
Number of subjects: 106
Study 18405821 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MT) only
Number of subjects: 106
Study 16364710 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement (PRO, Myoplex, EAS, Inc. Golden CO) containing 280 kcal, 42 g protein, 21 g carbohydrate, and 1.5 g fat
Number of subjects: 52
Study 16364710 — intervention group
Group type: COMPARATOR
Intervention: Calorically equivalent carbohydrate control (CS)
Number of subjects: 52
Study 11933115 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysaccharide fraction isolated from Echinacea purpurea (EPS‐EPO VIIa)
Number of subjects: 15
Study 11933115 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no intervention)
Number of subjects: 15
Study 9457544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reinforced poly-L-lactide (SR-PLLA) screws
Number of subjects: 21
Study 9457544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic cannulated screws
Number of subjects: 21
Study 9457544 — intervention group
Group type: COMPARATOR
Intervention: Control (nonoperated pairs)
Number of subjects: 21
Study 8554733 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg daily)
Number of subjects: 60
Study 8554733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2151046 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 42
Study 2151046 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 42
Study 27546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam
Number of subjects: 17
Study 27546 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 17
Study 27546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate
Number of subjects: 17
Study 27546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6127963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophyllamine (maximal mean plasma concentration of 16.7 +/- 1.21 micrograms/ml)
Number of subjects: 6
Study 6127963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline (five inhalations)
Number of subjects: 6
Study 6127963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline (equipotent doses)
Number of subjects: 6
Study 6127963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbutaline (equipotent doses)
Number of subjects: 6
Study 31626158 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetophoretic diclofenac gel delivery using a traveling magnetic field (intensity, 20 mT; frequency, 6.25 Hz; exposure 20 min, 12 sessions)
Number of subjects: 65
Study 31626158 — intervention group
Group type: COMPARATOR
Intervention: Placebo magnetotherapy with diclofenac without magnetic field
Number of subjects: 65
Study 31626158 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency pulse magnetotherapy with traveling magnetic field without topical diclofenac therapy
Number of subjects: 65
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehypertension
Number of subjects: 2830
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2830
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: High HbA1c (6.0-6.4%)
Number of subjects: 2830
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined presence of hypertension and high HbA1c
Number of subjects: 2830
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP ≥ 130 mmHg
Number of subjects: 2830
Study 29380232 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP ≥ 80 mmHg
Number of subjects: 2830
Study 26655582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma (CAP) applied for 90 seconds to a defined skin area of 22.5 cm(2)
Number of subjects: 20
Study 24447503 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 28
Study 24447503 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 28
Study 22253252 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA)
Number of subjects: 32
Study 22253252 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 32
Study 20808257 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention combining electronic medical record based audit and feedback, practice site visits for academic detailing and participatory planning, and 'best-practice' dissemination
Number of subjects: 68150
Study 20808257 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 68150
Study 20808257 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 68150
Study 17686440 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with gemcitabine after first-line therapy
Number of subjects: 0
Study 17686440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 17686440 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 17686440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding bevacizumab to standard treatment
Number of subjects: 0
Study 17686440 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based doublet with an additional cytotoxic agent
Number of subjects: 0
Study 16300171 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac potassium (HANA)
Number of subjects: 18
Study 16300171 — intervention group
Group type: COMPARATOR
Intervention: diclofenac sodium (Shinpoong)
Number of subjects: 18
Study 11981352 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI plus quetiapine
Number of subjects: 27
Study 11981352 — intervention group
Group type: COMPARATOR
Intervention: SRI plus placebo
Number of subjects: 27
Study 9495269 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet
Number of subjects: 28
Study 9495269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Number of subjects: 28
Study 9495269 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet
Number of subjects: 28
Study 7696057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, neuromuscular blockers
Number of subjects: 100
Study 7696057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol and intermittent fentanyl (TIVA) with tracheal tube, no neuromuscular blocker (Group 2)
Number of subjects: 100
Study 7696057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol and intermittent fentanyl (TIVA) with LMA, no neuromuscular blocker (Group 4)
Number of subjects: 100
Study 7696057 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous propofol and intermittent fentanyl (TIVA) with LMA, neuromuscular blockers (Group 3)
Number of subjects: 100
Study 7696057 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 100
Study 7696057 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 100
Study 2654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 75 mg daily
Number of subjects: 10
Study 2654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine 150 mg daily
Number of subjects: 10
Study 2654200 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 10
Study 2654200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 299813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 93
Study 299813 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 93
Study 299813 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation and placebo device
Number of subjects: 93
Study 31150315 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 cycles of fluorouracil, leucovorin, and oxaliplatin) before fluorouracil/oxaliplatin CRT (50.4 Gy)
Number of subjects: 306
Study 31150315 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after CRT
Number of subjects: 306
Study 28401821 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 6693
Study 28401821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6693
Study 24730602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (ABB) alone (n = 12)
Number of subjects: 19
Study 24730602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (ABB) plus autologous bone (AB) in a 1/1 ratio (n = 7)
Number of subjects: 19
Study 23868149 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebrospinal venous insufficiency criteria met by pediatric patients with MS (n = 2) and young adult with pediatric-onset MS (n = 1).
Number of subjects: 65
Study 23868149 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging measures of intracerebral flow in pediatric patients with MS meeting chronic cerebrospinal venous insufficiency criteria (0.85 ± 0.11).
Number of subjects: 65
Study 23868149 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and disease characteristics of patients with MS meeting chronic cerebrospinal venous insufficiency criteria (n = 3).
Number of subjects: 65
Study 23868149 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound findings in participants.
Number of subjects: 65
Study 22151937 — intervention group
Group type: EXPERIMENTAL
Intervention: Samphire formulations (0.1% serum, 0.05% cream, serum-cream association, 0.5% silicone oil)
Number of subjects: 12
Study 22151937 — intervention group
Group type: COMPARATOR
Intervention: Placebo-preconditioned (silicone oil)
Number of subjects: 12
Study 22151937 — intervention group
Group type: COMPARATOR
Intervention: Untreated sites
Number of subjects: 12
Study 20175799 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of ascorbic acid and 400 IU of alpha‐tocopherol (treatment group)
Number of subjects: 75
Study 20175799 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (placebo group)
Number of subjects: 75
Study 20175799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study 16466469 — intervention group
Group type: EXPERIMENTAL
Intervention: ATHENA intervention (8-session program, coach-facilitated, peer-led)
Number of subjects: 0
Study 16466469 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study 15239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolucent cushioning pad (MammoPad) used during mammography
Number of subjects: 512
Study 15239794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cushioning pad)
Number of subjects: 512
Study 15239794 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolucent cushioning pad (MammoPad)
Number of subjects: 512
Study 12515705 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 300
Study 12515705 — intervention group
Group type: COMPARATOR
Intervention: Standard Wedged Treatment
Number of subjects: 300
Study 12515705 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 300
Study 9568554 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical process improvement activities across multiple hospitals and ambulatory physician sites
Number of subjects: 0
Study 7544845 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 4 years
Number of subjects: 27
Study 7544845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2230061 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 75
Study 2230061 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 75
Study 2230061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 348534 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable serenace in dextrose base
Number of subjects: 0
Study 348534 — intervention group
Group type: COMPARATOR
Intervention: Injectable serenace in saline base
Number of subjects: 0
Study 31828941 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 step program
Number of subjects: 35
Study 30900436 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 30